Nizatidine

Drug #521

Nizatidine is oral H-2-receptor antagonist similar to cimetidine, famotidine, and ranitidine. It currently is indicated for gastroesophageal reflux disease (GERD), short-term and maintenance treatment of duodenal ulcer, and short-term treatment of active benign gastric ulcer. It was originally approved by the FDA in April 1988. It competitively inhibits the binding of histamine to the H-2-receptors on the gastric basolateral membrane of parietal cells, reducing basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin. It may aid in gastromucosal healing, and it may protect the mucosa from the irritant effects caused by aspirin and nonsteroidal antiinflammatory agents..

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Ethenediamine.

It belongs to H2 and 5HT antagonist pharmacological group on the basis of mechanism of action. It is also classified under Histamine (H-2) Antagonists .

Molecular Weight: 331.5 · Solubility in Water: soluble · Solubility in Alcohol: soluble · Non-proprietary name: Nizatidine.

Pharmacokinetics

Absorption: Nizatidine has an oral bioavailability is 77.5% (±7.5%), pre-systemic (first-pass) metabolism accounts for 4.5% (±2.5%).

Distribution: Nizatidine has a volume of distribution is 1 l/kg. plasma protein binding is 30 %.

Elimination: it is metabolised via partially Hepatic, plasma half-life is 1.55 hr, renal excretion is 90 %.

Indications

Nizatidine is primarily indicated in conditions like Benign gastric ulcer, Benign gastric, duodenal or NSAID-associated ulceration, Duodenal ulcer, Gastro-oesophageal reflux disease, Peptic ulcer, Reflux oesophagitis.

Nizatidine is also indicated for secondary conditions like Dyspepsia.

Contraindications

None recorded.

Dosage

Nizatidine's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
150 mg	150 mg	Every 12h	PO	Maintenance dosr at night intially.
150 mg	150 mg	Every 24h	PO
Paediatric Dosage (20kg)
0 – 0	—	—		Not recommended for this age group
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

4 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

The signs and symptoms that are produced after acute overdosage of Nizatidine are Emesis, Miosis, Salivation , Diarrhea, Lacrimation.

Nizatidine is known to cause more or less tolerable side effects which are usually transient. These include SomnolenceX, SweatingX, Urticaria.

Warnings / Precautions

Nizatidine should be used with caution in patients with impaired kidney or liver function. Intravenous injection should be given slowly and intravenous infusion is recommended in patients with cardiovascular impairment.

Interference in Pathology

Nizatidine may interfere in the diagnosis of Elevations of SGPT and SGOT .

Available Brands

Click on a strength to view available brands.

Single Ingredient

Caps

300 mg

Storage Conditions

Nizatidine should be stored Caps.

Drug Classification

1.17.1.2 — Anti-peptic ulcerants

Manufacturers

Manufacturers of Nizatidine in Pakistan:

Xenon